NEUROCRINE BIOSCIENCES INC Payments to Acquire Investments
NEUROCRINE BIOSCIENCES INC (NBIX) reported Payments to Acquire Investments of $116.31 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-04-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2019-04-29
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for the quarter ending 2019-03-31 was $116.31M, a 16.54% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for the quarter ending 2018-12-31 was $216.67M, a 56.03% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for the quarter ending 2018-09-30 was $105.21M, a 32.33% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for the quarter ending 2018-06-30 was $84.72M, a 72.42% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for fiscal 2018 was $545.96M, a 6.42% decline from fiscal 2017.
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for fiscal 2017 was $583.41M, a 95.27% increase from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for fiscal 2016 was $298.78M, a 33.47% decline from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC payments to acquire investments for fiscal 2015 was $449.05M, a 74.36% increase from fiscal 2014.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2019-03-31 | $116.31M 10-Q · filed 2019-04-29 | $332.98M derived: sum of 2 quarters · filed 2019-04-29 | $438.19M derived: sum of 3 quarters · filed 2019-04-29 | $522.91M derived: sum of 4 quarters · filed 2019-04-29 |
| 2018-12-31 | $216.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $321.89M derived: sum of 2 quarters · filed 2019-02-08 | $406.61M derived: sum of 3 quarters · filed 2019-02-08 | $545.96M 10-K · filed 2019-02-08 |
| 2018-09-30 | $105.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $189.94M derived: sum of 2 quarters · filed 2018-11-05 | $329.29M 10-Q · filed 2018-11-05 | $468.16M derived: sum of 4 quarters · filed 2019-04-29 |
| 2018-06-30 | $84.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $224.08M 10-Q · filed 2018-07-31 | $362.95M derived: sum of 3 quarters · filed 2019-04-29 | $442.45M derived: sum of 4 quarters · filed 2019-04-29 |
| 2018-03-31 | $139.35M 10-Q · filed 2019-04-29 | $278.22M derived: sum of 2 quarters · filed 2019-04-29 | $357.73M derived: sum of 3 quarters · filed 2019-04-29 | $664.88M derived: sum of 4 quarters · filed 2019-04-29 |
| 2017-12-31 | $138.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $218.38M derived: sum of 2 quarters · filed 2019-02-08 | $525.53M derived: sum of 3 quarters · filed 2019-02-08 | $583.41M 10-K · filed 2019-02-08 |
| 2017-09-30 | $79.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $386.66M derived: sum of 2 quarters · filed 2018-11-05 | $444.54M 10-Q · filed 2018-11-05 | $526.17M derived: sum of 4 quarters · filed 2019-02-08 |
| 2017-06-30 | $307.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $365.03M 10-Q · filed 2018-07-31 | $446.67M derived: sum of 3 quarters · filed 2019-02-08 | $494.32M derived: sum of 4 quarters · filed 2019-02-08 |
| 2017-03-31 | $57.88M 10-Q · filed 2018-04-30 | $139.51M derived: sum of 2 quarters · filed 2019-02-08 | $187.16M derived: sum of 3 quarters · filed 2019-02-08 | $301.09M derived: sum of 4 quarters · filed 2019-02-08 |
| 2016-12-31 | $81.64M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $129.29M derived: sum of 2 quarters · filed 2019-02-08 | $243.22M derived: sum of 3 quarters · filed 2019-02-08 | $298.78M 10-K · filed 2019-02-08 |
| 2016-09-30 | $47.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $161.58M derived: sum of 2 quarters · filed 2017-11-01 | $217.14M 10-Q · filed 2017-11-01 | $289.76M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $113.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $169.49M 10-Q · filed 2017-08-03 | $242.10M derived: sum of 3 quarters · filed 2018-02-13 | $331.68M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $55.56M 10-Q · filed 2017-05-09 | $128.18M derived: sum of 2 quarters · filed 2018-02-13 | $217.75M derived: sum of 3 quarters · filed 2018-02-13 | $345.39M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $72.61M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $162.19M derived: sum of 2 quarters · filed 2018-02-13 | $289.83M derived: sum of 3 quarters · filed 2018-02-13 | $449.05M 10-K · filed 2018-02-13 |
| 2015-09-30 | $89.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $217.22M derived: sum of 2 quarters · filed 2016-11-02 | $376.44M 10-Q · filed 2016-11-02 | $392.82M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $127.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $286.86M 10-Q · filed 2016-08-03 | $303.25M derived: sum of 3 quarters · filed 2017-02-14 | $336.07M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $159.22M 10-Q · filed 2016-05-05 | $175.61M derived: sum of 2 quarters · filed 2017-02-14 | $208.43M derived: sum of 3 quarters · filed 2017-02-14 | $307.86M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $16.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $49.21M derived: sum of 2 quarters · filed 2017-02-14 | $148.64M derived: sum of 3 quarters · filed 2017-02-14 | $257.54M 10-K · filed 2017-02-14 |
| 2014-09-30 | $32.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $132.25M derived: sum of 2 quarters · filed 2015-10-29 | $241.16M 10-Q · filed 2015-10-29 | $256.11M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $99.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29 | $208.34M 10-Q · filed 2015-07-29 | $223.29M derived: sum of 3 quarters · filed 2016-02-11 | $258.05M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $108.91M 10-Q · filed 2015-04-30 | $123.86M derived: sum of 2 quarters · filed 2016-02-11 | $158.62M derived: sum of 3 quarters · filed 2016-02-11 | $187.73M derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $14.95M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $49.72M derived: sum of 2 quarters · filed 2016-02-11 | $78.83M derived: sum of 3 quarters · filed 2016-02-11 | $145.33M 10-K · filed 2016-02-11 |
| 2013-09-30 | $34.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $63.88M derived: sum of 2 quarters · filed 2014-11-04 | $130.38M 10-Q · filed 2014-11-04 | $157.19M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-06-30 | $29.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $95.61M 10-Q · filed 2014-08-06 | $122.42M derived: sum of 3 quarters · filed 2015-02-09 | $138.76M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-03-31 | $66.50M 10-Q · filed 2014-05-01 | $93.31M derived: sum of 2 quarters · filed 2015-02-09 | $109.65M derived: sum of 3 quarters · filed 2015-02-09 | $157.43M derived: sum of 4 quarters · filed 2015-02-09 |
| 2012-12-31 | $26.81M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $43.15M derived: sum of 2 quarters · filed 2015-02-09 | $90.93M derived: sum of 3 quarters · filed 2015-02-09 | $166.31M 10-K · filed 2015-02-09 |
| 2012-09-30 | $16.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $64.12M derived: sum of 2 quarters · filed 2013-10-29 | $139.50M 10-Q · filed 2013-10-29 | $174.42M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $47.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | $123.16M 10-Q · filed 2013-07-26 | $158.07M derived: sum of 3 quarters · filed 2014-02-11 | $186.38M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $75.39M 10-Q · filed 2013-05-02 | $110.30M derived: sum of 2 quarters · filed 2014-02-11 | $138.60M derived: sum of 3 quarters · filed 2014-02-11 | $163.84M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $34.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $63.22M derived: sum of 2 quarters · filed 2014-02-11 | $88.45M derived: sum of 3 quarters · filed 2014-02-11 | $139.10M 10-K · filed 2014-02-11 |
| 2011-09-30 | $28.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $53.54M derived: sum of 2 quarters · filed 2012-10-31 | $104.19M 10-Q · filed 2012-10-31 | $135.38M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-06-30 | $25.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-31 | $75.88M 10-Q · filed 2012-07-31 | $107.07M derived: sum of 3 quarters · filed 2013-02-08 | $138.94M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-03-31 | $50.65M 10-Q · filed 2012-05-02 | $81.84M derived: sum of 2 quarters · filed 2013-02-08 | $113.71M derived: sum of 3 quarters · filed 2013-02-08 | |
| 2010-12-31 | $31.20M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $63.06M derived: sum of 2 quarters · filed 2013-02-08 | $89.79M 10-K · filed 2013-02-08 | |
| 2010-09-30 | $31.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $58.59M 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | $26.72M 10-Q · filed 2011-07-29 | |||
| 2009-12-31 | $16.80M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |